Advertisement

Advertisement

ESMO World Congress on Gastrointestinal Cancer 2021

Colorectal Cancer

BRAF-Mutant Colorectal Cancer: Latest Findings for Targeted Treatment

The phase II ANCHOR CRC study, the largest prospective study of BRAF inhibitor–based therapy as first-line treatment of metastatic colorectal cancer, has met its primary endpoint, with 47.8% of patien...

Colorectal Cancer
Immunotherapy

Eric Deutsch, MD, PhD, Comments on the Averectal and AVANA Trials in Rectal Cancer

Eric Deutsch, MD, PhD, Professor and Chair of Radiation Oncology at Gustave Roussy, Villejuif, France, commended the speakers for conducting trials whose results he found “very interesting.” The Avere...

Colorectal Cancer
Immunotherapy

Avelumab Under Study as Adjunct to Neoadjuvant Therapy for Rectal Cancer

In the treatment of newly diagnosed locally advanced rectal cancer, two phase II studies evaluating the addition of the PD-L1 inhibitor avelumab to chemoradiotherapy showed promising rates of patholog...

Pancreatic Cancer
Immunotherapy

Tackling the Challenge of Pancreatic Cancer: New Approaches

Pancreatic cancer remains an incorrigible foe, but recent advances in genomic profiling and targeted drug development are slowly improving the outlook for patients, according to Eileen M. O’Reilly, MD...

Gastroesophageal Cancer
Immunotherapy

Expert Point of View: Kei Muro, MD, PhD

The RATIONALE 302 trial1 was discussed by Kei Muro, MD, PhD, of Aichi Cancer Center Hospital in Nagoya, Japan, who found the results promising. However, Dr. Muro questioned the role of PD-1/L1 inhibit...

Gastroesophageal Cancer
Immunotherapy

RATIONALE 302: Tislelizumab Improves Overall Survival as Second-Line Treatment of Esophageal Cancer

In the phase III RATIONALE 302 trial, the novel anti–PD-1 antibody tislelizumab, being developed in China, improved overall survival vs chemotherapy as second-line therapy for esophageal squamous cell...

Pancreatic Cancer

Expert Point of View: Thomas Seufferlein, MD, PhD

The invited discussant of APACT,1 Thomas Seufferlein, MD, PhD, Professor of Medicine at the University of Ulm in Germany, said the updated overall survival data “suggest an improved outcome with nab-p...

Pancreatic Cancer

APACT: 5-Year Overall Survival Data Suggest Improved Outcomes in Pancreatic Cancer With Nab-paclitaxel/Gemcitabine

The 5-year outcomes in the APACT trial uphold the overall survival benefit with nab-paclitaxel plus gemcitabine in the adjuvant treatment of patients with resected pancreatic cancer, according to Marg...

Immunotherapy
Gastrointestinal Cancer

RATIONALE 208: ‘Durable Clinical Activity’ Reported With Tislelizumab in Advanced Liver Cancer

With the investigational checkpoint inhibitor tislelizumab, durable responses were achieved by some patients with previously treated advanced hepatocellular carcinoma, regardless of the number of prio...

Gastrointestinal Cancer
Issues in Oncology

Effect of Obesity on Receipt of Chemotherapy in Patients With Colorectal Cancer

Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy relative to their body surface area than nonobese patients, according to results from a large meta-analysi...

Pancreatic Cancer

Expert Point of View: Thomas Seufferlein, MD, PhD

The invited discussant of APACT,1 Thomas Seufferlein, MD, PhD, Professor of Medicine at the University of Ulm in Germany, said the updated overall survival data “suggest an improved outcome with nab-p...

Gastrointestinal Cancer
Immunotherapy

DESTINY-Gastric01 Exploratory Biomarker Analysis Examines Efficacy of Trastuzumab Deruxtecan-nxki Among Patients With HER2-Positive and HER2-Low Gastric Cancer

Trastuzumab deruxtecan-nxki demonstrated clinically meaningful benefit across specific subgroups of patients with HER2-positive and HER2-low advanced gastric cancer, according to findings from a post ...

Pancreatic Cancer

APACT: 5-Year Overall Survival Data Suggest Improved Outcomes in Pancreatic Cancer With Nab-Paclitaxel Plus Gemcitabine

Five-year outcomes in the APACT trial uphold the overall survival benefit with nab-paclitaxel plus gemcitabine in the adjuvant treatment of patients with resected pancreatic cancer, according to Marga...

Colorectal Cancer

Is There a Link Between Use of Antibiotics and Early-Onset Colorectal Cancer?

Study findings presented by Perrott et al at the ESMO World Congress on Gastrointestinal Cancer (Abstract SO-25) showed that the use of antibiotics may be linked to colon tumor formation across all pa...

Colorectal Cancer

Using ctDNA to Measure Molecular Residual Disease in Patients With Colorectal Cancer

A team of investigators in Japan used a personalized assay for circulating tumor DNA (ctDNA) levels in plasma to monitor molecular residual disease following surgery in patients with resectable colore...

Advertisement

Advertisement



Advertisement